PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates.

Darren R Veach Claire M Storey Katharina LückerathKatharina BraunChristian von BodmanUrpo LamminmäkiTeja KalidindiSven-Erik StrandJoanna StrandMohamed AltaiRobert DamoiseauxPat ZanzonicoNadia BenabdallahDmitry PankovHoward I ScherPeter ScardinoSteven M Larson Hans G LiljaMichael R McDevittDaniel L J ThorekDavid Ulmert

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

We present a complete preclinical evaluation of radiolabeled hu5A10 in mouse prostate cancer models and NHPs, and establish hu5A10 as a new theranostic agent that allows highly specific and effective downstream targeting of AR in PSA-expressing tissue. Our data support the clinical translation of radiolabeled hu5A10 for treating prostate cancer.

Keyphrases

prostate cancer
radical prostatectomy
cancer therapy
quantum dots
electronic health record
mesenchymal stem cells
deep learning
data analysis
energy transfer